A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLCHelai P. Mohammad, Ryan G. Kruger, Kelly Federowicz et al.|Cancer Cell|2015Cited by 518
Abstract 4700: A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutationsCaretha L. Creasy, Peter J. Tummino, Michael T. McCabe et al.|Cancer Research|2012Cited by 3